Details

Autor(en) / Beteiligte

• RIJNSBURGER, Adriana J
• OBDEIJN, Inge-Marie
• PETERSE, Hans
• TOLLENAAR, Rob A. E. M
• HOOGERBRUGGE, Nicoline
• MEIJER, Sybren
• BARTELS, Carina C. M
• SEYNAEVE, Caroline
• HOONING, Maartje J
• KRIEGE, Mieke
• SCHMITZ, Paul I. M
• OOSTERWIJK, Jan C
• KAAS, Reinoutje
• DE KONING, Harry J
• RUTGERS, Emiel J. T
• KLIJN, Jan G. M
• TILANUS-LINTHORST, Madeleine M. A
• BOETES, Carla
• LOO, Claudette E
• WASSER, Martin N. J. M
• BERGERS, Elisabeth
• KOK, Theo
• MULLER, Sara H

Titel

BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study

Ist Teil von

• Journal of clinical oncology, 2010-12, Vol.28 (36), p.5265-5273

Ort / Verlag

Alexandria, VA: American Society of Clinical Oncology

Erscheinungsjahr

2010

Quelle

MEDLINE

Beschreibungen/Notizen

• The Dutch MRI Screening Study on early detection of hereditary breast cancer started in 1999. We evaluated the long-term results including separate analyses of BRCA1 and BRCA2 mutation carriers and first results on survival. Women with higher than 15% cumulative lifetime risk (CLTR) of breast cancer were screened with biannual clinical breast examination and annual mammography and magnetic resonance imaging (MRI). Participants were divided into subgroups: carriers of a gene mutation (50% to 85% CLTR) and two familial groups with high (30% to 50% CLTR) or moderate risk (15% to 30% CLTR). Our update contains 2,157 eligible women including 599 mutation carriers (median follow-up of 4.9 years from entry) with 97 primary breast cancers detected (median follow-up of 5.0 years from diagnosis). MRI sensitivity was superior to that of mammography for invasive cancer (77.4% v 35.5%; P<.00005), but not for ductal carcinoma in situ. Results in the BRCA1 group were worse compared to the BRCA2, the high-, and the moderate-risk groups, respectively, for mammography sensitivity (25.0% v 61.5%, 45.5%, 46.7%), tumor size at diagnosis≤1 cm (21.4% v 61.5%, 40.9%, 63.6%), proportion of DCIS (6.5% v 18.8%, 14.8%, 31.3%) and interval cancers (32.3% v 6.3%, 3.7%, 6.3%), and age at diagnosis younger than 30 years (9.7% v 0%). Cumulative distant metastasis-free and overall survival at 6 years in all 42 BRCA1/2 mutation carriers with invasive breast cancer were 83.9% (95% CI, 64.1% to 93.3%) and 92.7% (95% CI, 79.0% to 97.6%), respectively, and 100% in the familial groups (n=43). Screening results were somewhat worse in BRCA1 mutation carriers, but 6-year survival was high in all risk groups.